机构:[1]Division of Rheumatology, Guang An Men Hospital, China Academy of Chinese Medical Science, Beijing 100053[2]Department of Dermatology, The First People's Hospital of Jingmen, Jingmen, Hubei 448000[3]Department of Dermatology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong 510000[4]Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China
Psoriasis is an immune‑mediated dermatosis characterized by T‑lymphocyte‑mediated epidermal hyperplasia, for which there are currently no effective clinical treatments. 'Psoriasis 1' is a Chinese herbal medicine formulation that has been recently used extensively in China for treating patients with psoriasis. However, the molecular mechanism of action of this potent formulation has not yet been fully elucidated. In the present study, the effects of 'Psoriasis 1' on T ymphocytes in patients with psoriasis were investigated and the underlying molecular mechanism was discussed. Blood samples were collected from 40 patients with psoriasis. ELISA was employed to assess the levels of tumour necrosis factor‑α, interferon‑γ, interleukin (IL)‑2, IL‑6, transforming growth factor‑β, IL‑4, IL‑12, IL‑23 and vitamin D (VD). Western blot and quantitative PCR analyses were used to investigate the expression levels of VD receptor (VDR) and signal transducer and activator of transcription (STAT)4 in T lymphocytes. 'Psoriasis 1' was observed to significantly increase CD4+ T cells. It also notably upregulated the mRNA and protein expression of VDR, and downregulated the mRNA and protein expression of STAT4. Moreover, the suppression of VDR was found to aggravate the inflammatory response, which was reversed by 'Psoriasis 1.' Thus, this formulation reportedly decreased the inflammation mediated by T lymphocytes in patients with psoriasis through inhibiting VDR‑mediated STAT4 inactivation.
基金:
The present study was financially supported by the National
Natural Science Foundation of China (grant. nos. 81573980
and 81673804), the Guangdong Science and Technology
Department Project (grant no. 2017A020215058), the Nature
Science Foundation of Hubei Province (grant no. 2018CFB289)
and the Science Foundation of Health Commission of Hubei
Province (grant. no. WJ2019M074).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类|3 区医学
小类|4 区医学:研究与实验
最新[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验
第一作者:
第一作者机构:[1]Division of Rheumatology, Guang An Men Hospital, China Academy of Chinese Medical Science, Beijing 100053
共同第一作者:
通讯作者:
通讯机构:[1]Division of Rheumatology, Guang An Men Hospital, China Academy of Chinese Medical Science, Beijing 100053[3]Department of Dermatology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong 510000[4]Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China[*1]Department of Dermatology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, 12 Airport Road, Baiyun, Guangzhou, Guangdong 510000, P.R. China[*2]Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng, Beijing 100700, P.R. China
推荐引用方式(GB/T 7714):
Gao Yang,Sun Wen,Cha Xushan,et al.'Psoriasis 1' reduces T‑lymphocyte‑mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor‑mediated STAT4 inactivation.[J].International journal of molecular medicine.2020,46(4):1538-1550.doi:10.3892/ijmm.2020.4695.
APA:
Gao Yang,Sun Wen,Cha Xushan&Wang Hailong.(2020).'Psoriasis 1' reduces T‑lymphocyte‑mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor‑mediated STAT4 inactivation..International journal of molecular medicine,46,(4)
MLA:
Gao Yang,et al."'Psoriasis 1' reduces T‑lymphocyte‑mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor‑mediated STAT4 inactivation.".International journal of molecular medicine 46..4(2020):1538-1550